Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIOMEDICAL RESEARCH S.R.L. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is located within 1 distinct art unit. This indicates a singular focus for the company's active patent prosecution. The concentration of the portfolio into 1 pending office action suggests that the company is currently prioritizing a specific technical advancement within the biotechnology sector.
BROWE, DAVID is the busiest examiner for the portfolio, managing 1 pending office action. This examiner is responsible for the 1 pending action currently active for the company. Prosecution strategy is centered on this individual examiner's review of the pending application. Because the entire active portfolio is under the jurisdiction of 1 examiner, the company's immediate success in the patent office is tied to the specific examination standards and preferences of this official.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWE, DAVID | 1 | 26.8% | +27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248825 | COMPOSITION BASED ON AUTOLOGOUS PLATELET CONCENTRATES AND A COLOSTRUM ISOLATE MIXTURE OF BIOLOGICAL FACTORS FOR USE IN THE TREATMENT OF CONDITIONS REQUIRING TISSUE REPAIR AND REGENERATION | BROWE, DAVID | 72d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248825 | COMPOSITION BASED ON AUTOLOGOUS PLATELET CONCENTRATES AND A COLOSTRUM ISOLATE MIXTURE OF BIOLOGICAL FACTORS FOR USE IN THE TREATMENT OF CONDITIONS REQUIRING TISSUE REPAIR AND REGENERATION | BROWE, DAVID | 72d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18248825 | COMPOSITION BASED ON AUTOLOGOUS PLATELET CONCENTRATES AND A COLOSTRUM ISOLATE MIXTURE OF BIOLOGICAL FACTORS FOR USE IN THE TREATMENT OF CONDITIONS REQUIRING TISSUE REPAIR AND REGENERATION | BROWE, DAVID | 1617 | §103§112 | Final Rejection | 72d overdue | Pending | Apr 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOMEDICAL RESEARCH S.R.L. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
David Browe has the most, with 1 of BIOMEDICAL RESEARCH S.R.L.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.